2008DMW - Deutsche Medizinische WochenschriftRequires access

Bromocriptin-induzierte zystische Tumorregression bei fortgeschrittenen Prolactinomen

G Galvan, Johanna Frick, T. Irnberger

Open publisher page 5 citations

Abstract

Conservative treatment with bromocriptine was performed in three patients with macroprolactinomas and increased prolactin levels. Lowering of prolactin levels to normal or subnormal values was possible in all cases. One extensive prolactinoma with retro- and suprasellar parts showed regression to a large extent and cystic degeneration. Transient occurrence of liquorrhoea is considered as a consequence of tumour regression. In cases of parasellar prolactinoma recurrence and intrasellar prolactinoma diminution and cystic degeneration were observed while on bromocriptine treatment. Bromocriptine dosage varied between 3.75 and 30 mg/d. Treatment was performed between 20 and 26 months. There were no serious side effects. Bromocriptine treatment offers an alternative to surgery in macroprolactinomas and prolactinoma recurrences.

About this research paper

What this paper is about

Conservative treatment with bromocriptine was performed in three patients with macroprolactinomas and increased prolactin levels. Lowering of prolactin levels to normal or subnormal values was possible in all cases. One extensive prolactinoma with retro- and suprasellar parts showed regression to a large extent and cystic degeneration. Transient occurrence of liquorrhoea is considered as a consequence of tumour regression. In cases of parasellar prolactinoma recurrence and intrasellar prolactinoma diminution and cystic degeneration were observed while on bromocriptine treatment. Bromocriptine dosage varied between 3.75 and 30 mg/d. Treatment was performed between 20 and 26 months. There were no serious side effects. Bromocriptine treatment offers an alternative to surgery in macroprolactinomas and prolactinoma recurrences.

Why it matters

OpenAlex reports 5 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Conservative treatment with bromocriptine was performed in three patients with macroprolactinomas and increased prolactin levels. Lowering of prolactin levels to normal or subnormal values was possible in all cases. One extensive prolactinoma with retro- and suprasellar parts showed regression to a large extent and cystic degeneration. Transient occurrence of liquorrhoea is considered as a consequence of tumour regression. In cases of parasellar prolactinoma recurrence and intrasellar prolactinoma diminution and cystic degeneration were observed while on bromocriptine treatment. Bromocriptine dosage varied between 3.75 and 30 mg/d. Treatment was performed between 20 and 26 months. There were no serious side effects. Bromocriptine treatment offers an alternative to surgery in macroprolactinomas and prolactinoma recurrences.

Key concepts: Bromocriptine, Prolactinoma, Medicine, Prolactin, Internal medicine, Hormone

Related papers

Back to paper searchBrowse research topicsOriginal source
Bromocriptin-induzierte zystische Tumorregression bei fortgeschrittenen Prolactinomen — Research Paper | ScholarLens